Dr. Shirish Gadgeel is Co-Leader of the Thoracic Oncology Team in the Comprehensive Cancer Center at Michigan Medicine at the University of Michigan as of May 2017. He also has been appointed Associate Director for Cancer Care (ADCC) at Networking and Affiliated Centers.
Prior to joining Michigan Medicine Dr. Gadgeel was the co-leader of the Molecular Therapeutics Program of the Karmanos Cancer Institute (KCI).
Dr. Gadgeel has conducted and participated in many lung cancer specific trials and has also been a principal investigator of a Southwest Oncology Group trial, S0528 and NCI protocol 7389. He has engaged in many epidemiologic studies in the field of lung cancer, publishing on features of lung cancer in African-Americans and young patients. He is currently the principal investigator of multi-PI R21 to identify ‘driver’ genetic alterations in African-American lung cancer patients.
Dr. Gadgeel’s clinical research experience spans 14 years. He is a member of the Steering Committees of the Early Therapeutics Committee and Lung Cancer Committee of Southwest Oncology Group (SWOG). He sits on the editorial boards of the medical journals, Clinical Lung Cancer and Cancer, and a reviewer for many others including Clinical Cancer Research, Lancet Oncology and the Journal of Thoracic Oncology. Dr. Gadgeel was awarded by the NCI the Cancer Clinical Investigator Team Leadership Award in 2012.
Speakers Bureau: Eli Lilly, Genentech, GlaxoSmithKline
Research Funding: AstraZeneca, Eli Lilly, Genentech